Just over a month after the FDA accepted Acacia Pharma Ltd.'s US NDA for its novel post-operative nausea and vomiting (PONV) therapy, Baremsis (a low-dose amisulpride injection), and received a PDUFA date of Oct. 5, 2018, the Cambridge, UK-based company announced on Feb. 5 its intention to launch an initial global offering (IGO) on Euronext in Brussels, to raise new funds to support its US marketing preparations.
"The choice of the Belgium exchange does not reflect anything negative about the UK, but is more a reflection of positives specific for Acacia," company CEO Julian Gilbert told Scrip....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?